NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

@WallStreetApes

How bad are things? Wall Street Market Makers are selling unlimited counterfeit shares & they are openly telling you they’re doing it

Doug Cifu (@Dougielarge): “If someone wants to buy 1,000 shares & only 200 are available, we will sell them 1,000. We call it unlimited… pic.twitter.com/tR5wDKydxj

— Wall Street Apes (@WallStreetApes) June 26, 2023

How bad are things? Wall Street Market Makers are selling unlimited counterfeit shares & they are openly telling you they’re doing it

Doug Cifu (
@Dougielarge
): “If someone wants to buy 1,000 shares & only 200 are available, we will sell them 1,000. We call it unlimited liquidity” Counterfeiting shares is illegal, it’s the exact same thing as counterfeiting money.

Maker Makers like Douglas A. Cifu of Virtu Financial and Ken Griffin of Citadel are openly telling you they are counterfeiting unlimited shares to meet “demand”. There’s only one problem, that’s not how supply and demand works.

What they are doing is not providing meaningful liquidity, instead they are flooding the market with counterfeiting shares. This DESTROYS share prices and obliterated retail investors portfolios. Supply & Demand doesn’t exist because they are creating an infinite supply.

Unlimited liquidity = unlimited counterfeit shares = unlimited fraud = unlimited share price drops = unlimited losses for retail investors

How can Wall Street openly get away with counterfeiting? They are robbing the entire world with fraud and every company listed on the New York stock exchange.

This has led to DEVASTATING losses for investors in stocks like AMC & GameStop where literally BILLIONS of shares have been counterfeited, wiping out hundreds of billions of dollars from investors portfolios

Ken Griffin is not speaking here but he is BY FAR one of the worst offenders and is Ron DeSantis’s MEGADONORS, all the money of course is stolen from retail.

This admission happened all the way back on June 8th, 2022, no one has done a thing to stop them. Everyone continues to look the other way and keep taking their lobbying money to look the other way.

$AMC $APE $GME GME #GameStop #NakedShorts #SEC #FINRA #DTCC
7:26 PM · Jun 26, 2023
·jfr1611

Re: eagle8 post# 604941

Tuesday, June 27, 2023 8:28:51 AM

Post#
604943
of 604944
I prefer to be conservative here but you never know when MHRA approves it.
It could come anytime between now and mid august.

ATLnsider

Re: Legend431 post# 599206

Tuesday, June 06, 2023 7:33:34 PM

Post#
599240
of 604944
Legend431, you’re right that NWBO is not valued at a billion dollars today. But, it is only a matter of time, and more milestones being achieved before NWBio is worth multiple tens of $billions, or even trillions.

Granted, this will take years, and for NWBio to successfully achieve several major positive milestones. Most of the NWBO investors here today will probably sell their shares long before the valuation of NWBio reach tens of billions, and especially trillions.

I took a quick look at how much NWBio will be worth, assuming the following:

(1) DCVax-L is approved initially in the US, UK, Canada, Germany and the rest of the EU.

(2) DCVax-L is approved in most of the rest of the world.

(3) DCVax-L is eventually approved as a tissue agnostic treatment for all or most solid tumor cancers. I gradually increased annual global patients each year.

(4) The average revenue per patient for DCVax-L starts out initially at $150,000 per patient. Then because of manufacturing efficiencies due to using Flaskworks devices, and economies of scale due to an increasing number of customers treated each year, the revenue per patient would gradually decrease by about 50%, from $150,000 down to $75,000.

(5) The average multiple of price to sales for a biotech drug company is 5.78. I used this multiple to calculate the total valuation of NWBio for each level of customers treated:

https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/psdata.html

(6) The value per share is initially based on 1.5 billion shares outstanding. I increased the number of outstanding shares to 1.6 billion shares after the annual number of cancer patients treated exceeded 10,000 patients per year.

Here are the results of these projections below. You can see an eventual valuation of over $1.73 trillion, which equates to $1,083.75 per share, based on 1.6 billion NWBO shares outstanding:


Bullish
BULLISH